Thailand’s cannabis sector experienced one of the most dramatic rises and regulatory pivots in Asia’s modern history. After full decriminalization in 2022 turned the country into a regional cannabis hub, a 2025 policy reversal shifted the industry toward a stricter medical framework. While many retail outlets closed, the underlying legal and medical market continues to show robust long-term growth potential.
The Rapid Rise (2022–Early 2025)
In June 2022, Thailand became the first nation in Asia to decriminalize cannabis, removing the plant—including its flowers—from the narcotics list. This built on earlier medical legalization in 2018–2019. The government actively promoted cannabis as a post-COVID economic driver, a new cash crop for farmers, and a boost for medical tourism.
Dispensaries sprang up across the country, reaching approximately 18,433 registered outlets by late 2024 and early 2025. Tourist hotspots such as Bangkok’s Khao San Road, Phuket, and Koh Samui saw dense clusters of shops, many operating with limited oversight and selling directly to visitors without prescriptions. The sector was estimated to generate between $1 billion and $1.3 billion annually at its peak, with visible cultural shifts: neon-lit storefronts, widespread edibles, and a thriving cannabis tourism scene.
Cultivation expanded quickly. Home growing was initially encouraged, with free seedlings distributed in some areas, while commercial farms—both indoor and outdoor—multiplied. Imported strains dominated the market, though foreign investment faced restrictions aimed at protecting local businesses.
The 2025 Regulatory Backlash
Unregulated expansion soon triggered public and political concerns. Reports highlighted increased youth access, a surge in cannabis-related health issues (including poisoning cases rising 3.5 times and higher addiction notifications), and the optics of overt “weed tourism.”
On June 25, 2025, the Public Health Ministry reclassified cannabis flower as a “controlled herb.” Recreational sales were banned, and purchases now require a prescription from a licensed doctor, traditional medicine practitioner, pharmacist, or dentist. Advertising faced new restrictions, and public consumption rules tightened.
The impact was immediate. Over 7,000 shops closed in 2025 as many failed to renew licenses or adapt to the new requirements. The remaining roughly 11,000 outlets face stricter inspections, mandatory record-keeping, and a shift toward medical or clinic-style operations. Further license expirations are expected in 2026–2027. Public use can still result in fines of up to 25,000 THB (about $700) or jail time for causing a nuisance. Sales to minors under 20 and pregnant or breastfeeding individuals remain prohibited. Low-THC hemp and CBD products (<0.2% THC) continue to enjoy relatively easier access.
Current Landscape and Future Outlook (2026)
On paper, Thailand operates a medical-only cannabis regime, though recreational possession and private use remain technically decriminalized but heavily restricted in practice. A comprehensive Cannabis and Hemp Act is still under development to provide clearer long-term rules.
Market projections for the legal and medical cannabis sector remain optimistic. One estimate placed the market at approximately $1.31 billion in 2024, forecasting growth to $1.7 billion in 2025 and $7.1 billion by 2030, reflecting a compound annual growth rate of around 33%. Other forecasts are even more bullish, though figures vary widely depending on assumptions about regulation and exports.
Key growth drivers include expanding medical applications for conditions such as epilepsy, chronic pain, and anxiety; research and development; potential exports; industrial hemp uses; and regulated tourism models. Challenges persist, however: political volatility (cannabis policy remains tied to parties like Bhumjaithai), oversupply hurting small operators, enforcement inconsistencies, and limits on foreign ownership.
What This Means for Visitors
Casual recreational access has significantly narrowed. Many remaining shops require Thai medical consultations for prescriptions or operate in legal gray zones. Low-THC edibles and CBD products are still relatively available, but public smoking carries risks of fines. Private use is generally tolerated if compliant, though tourist areas face closer scrutiny.
Thailand’s “green rush” delivered swift economic and cultural impact but also demonstrated the challenges of rapid liberalization without robust safeguards. The industry is now consolidating into a more professional, medically oriented sector with substantial long-term promise—particularly in medical innovation and hemp applications. As policies continue to evolve with shifting politics, visitors and investors should consult official Thai FDA sources or embassies for the most current regulations.
About The Author
